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Abstract
Rationale The driving simulator provides a safe and controlled
environment for testing driving behaviour efficiently. The ques-
tion is whether it is sensitive to detect drug-induced effects.
Objective The primary aim of the current study was to inves-
tigate the sensitivity of the driving simulator for detecting drug
effects. As a case in point, we investigated the dose-related
effects of oral Δ9-tetrahydrocannabinol (THC), i.e.
dronabinol, on simulator and on-the-road driving performance
in equally demanding driving tasks.
Method Twenty-four experienced driver participants were treat-
ed with dronabinol (Marinol®; 10 and 20 mg) and placebo.
Dose-related effects of the drug on the ability to keep a vehicle
in lane (weaving) and to follow the speed changes of a lead car
(car following) were compared within subjects for on-the-road
versus in-simulator driving. Additionally, the outcomes of equiv-
alence testing to alcohol-induced effects were investigated.
Results Treatment effects found onweavingwhen driving in the
simulator were comparable to treatment effects found when driv-
ing on the road. The effect after 10 mg dronabinol was however
less strong in the simulator than on the road and inter-individual
variance seemed higher in the simulator. There was, however, a
differential treatment effect of dronabinol on reactions to speed
changes of a lead car (car following) when driving on the road
versus when driving in the simulator.
Conclusion The driving simulator was proven to be sensitive
for demonstrating dronabinol-induced effects particularly at
higher doses. Treatment effects of dronabinol on weaving
were comparable with driving on the road but inter-
individual variability seemed higher in the simulator than on
the road which may have potential effects on the clinical in-
ferences made from simulator driving. Car following on the
road and in the simulator were, however, not comparable.
Keywords Driving simulator . Driving performance .
Dronabinol . Equivalence testing . Predictive validity . THC
Introduction
The driving simulator is widely used to study driving behav-
iour (Wachtel 1995) mostly because it provides a safe and
relatively controlled way of testing driving behaviour effi-
ciently. This means that in the simulator we can safely inves-
tigate potential risks to traffic safety that are not safe to test on
the road, for example, impaired driving as a consequence of
the intake of medicines, drugs or alcohol. This is important
because studies on the influence of such substances on driving
performance can generate knowledge about fitness to drive
after using these substances. Even so, the usability of the driv-
ing simulator for testing fitness to drive depends on its ability
to elicit behaviour in the virtual environment that would also
be displayed in the real world. In other words, the usability of
the driving simulator as a means of investigating drug-induced
effects on driving performance depends on its predictive va-
lidity, and it is this predictive validity that is often questioned
(see for example Mullen et al. 2012 in Fisher et al. 2011).
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The questions about the predictive validity of the driving
simulator are usually two threaded (Fisher et al. 2011). If the
numerical values between the naturalistic and the simulator
data are equivalent, then ‘absolute’ validity can be claimed
(Blaauw 1982; Godley et al. 2002). However, for a simulator
to be a valid instrument for research, absolute validity is not
essential (Törnros 1998). Research questions usually deal with
matters relating to the effects of independent variables on de-
pendent variables, rather than seeking to determine absolute
numerical measurements of driver behaviour. Therefore, a
second approach is to establish whether the same trend of
effect is found for the driving simulator and on the road tests,
assessing relative validity (Blaauw 1982; Godley et al. 2002).
Previous validation studies have usually investigated a spe-
cific task to determine if the simulator was a valid instrument
of measurement in that specific case. Examples of these are
studies on tasks such as keeping speed (Blaauw 1982; Törnros
1998; Bella 2008; Shinar and Ronen 2007) or lateral control
(Blaauw 1982; Törnros 1998), braking (McGehee et al. 2000;
Hoffman et al. 2002), responding to road markings (Godley
et al. 2002) and studies on driver errors (Shechtman et al.
2009). These studies generally have reported that driving in
the simulator corresponds fairly well to on-road driving (see
also Fisher et al. 2011). Even so, Volkerts et al. (1992)
questioned whether the driving simulator would also be sen-
sitive enough to detect drug-induced effects.
Generally, driving simulator studies investigating the ef-
fects of different types of drugs and alcohol on driving perfor-
mance show a similar trend of effect in the simulator as are
also reported in on-the-road studies. For example, in two driv-
ing simulator studies conducted by Mets et al. (2011) and
Veldstra et al. (2011), the same dose-dependent relationship
between alcohol and standard deviation of the lateral position
(SDLP) was reported that was also reported in an on-the-road
driving study by Louwerens et al. (1987). Direct within-
subjects comparisons between drug-induced effects in simu-
lated and on-the-road driving are, however, sparse.
As far as is known to us, only Volkerts et al. (1992) con-
ducted such a study. In this study, the residual effects of noc-
turnal treatments with hypnotics (i.e. lormetazepam 1 mg and
oxazepam 50 mg) on simulated driving performance were
compared to on-the-road driving performance. They found
that the main parameter in the on-the-road task (SDLP) was
sensitive to the verum, whereas simulated tracking perfor-
mance was not. Volkerts et al. (1992) concluded that this
difference was due to a lack of sensitivity of the driving
simulator but proposed an alternative explanation as well.
The simulator task was a curve following task, inducing a
relatively high state of vigilance, which was more closely
related to city driving, whereas the on-the-road driving
test was a simple motorway driving task, inducing a rel-
atively low vigilance state. The difference in drug effects
could therefore also be attributed to a difference in task
demands. Therefore, the primary aim of the present study
was to investigate the sensitivity of the driving simulator
for detecting drug effects in equally demanding driving
tasks.
As a case in point, we investigated the dose-related effects of
two dosages of oral cannabis (dronabinol; 10 and 20 mg) and
placebo on driving performance. Testing the effects of Δ9-tetra-
hydrocannabinol (THC) on driving performance is important
because the use of cannabis (in which THC is the primary active
compound) is widespread throughout the world, and it is the
most frequently detected illicit drug found in impaired drivers
(Hartman and Heustis 2013). And although the influence of
THC on driving performance has been tested before, both on
the road in actual traffic (Ramaekers et al. 2000; Robbe 1994,
1998; Bosker et al. 2012a, b) and in the driving simulator (Lenné
et al. 2010; Liguori et al. 2002; Ménétrey et al. 2005; Sexton
et al. 2000), outcomes are difficult to compare because experi-
mental setups and performance measures are usually dissimilar.
In the current study, we therefore tested in a within-subjects
design whether driving simulator and the on-the-road driving
tests were equally sensitive to detect dose-related effects of
dronabinol on driving performance. Performance measures that
were used are: the road tracking test as developed by O’Hanlon
et al. (1982) and the car following test adapted from Brookhuis
et al. (1994). Both tests have been used in numerous studies
testing the effects of psychoactive substances on driving
performance such as: alcohol (Veldstra et al. 2011; Mets et al.
2011), amphetamines (Simons et al. 2011), MDMA (Bosker
et al. 2012a; Kuypers et al. 2006; Veldstra et al. 2011), hypnotics
(Leufkens et al. 2007), anti-depressants (Wingen et al. 2006) and
anti-histamines (Ramaekers and O’Hanlon 1994). Moreover, the
main performance measure in the road tracking task, SDLP, has
been calibrated on the road for alcohol-induced performance
effects in such a way that clinically relevant performance incre-
ments can be expressed in equivalent BACs (Louwerens et al.
1987) using so-called equivalence tests.
The present work was part of a larger study on the effects of
dronabinol on driving performance (Bosker et al. 2012a, b). In this
paper, we tested whether the simulator and the on-the-road driving
tests generated equal results in terms of clinical relevance.
Methods and materials
Participants
Twenty-four participants (14 male, 10 female) with an average
age of 23.6 years (SD=3.0) participated in a study on the
effects of dronabinol on driving performance (for details, see
Bosker et al. 2012b). Participants were experienced drivers
who were in the possession of a valid driving licence over
3 years with a minimum mileage of 5000 km per year. This
study was conducted in accord with the code of ethics on
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human experimentation established by the Declaration of Hel-
sinki (latest revision, Seoul 2008) and in accordance with the
Medical Research Involving Human Subjects Act (WMO).
Approval for the studies was obtained from the Maastricht
Academic Hospital’s Medical Ethics committee. A written
informed consent was obtained from every participant. Partic-
ipants were compensated for their participation by means of a
monetary contribution and were driven home at the end of
each testing day.
Study design and treatment
The study was conducted according to a double-blind, place-
bo-controlled, crossover design with treatment orders but not
driving conditions counter-balanced. The treatments consisted
of a single dose of dronabinol (10 and 20 mg) and placebo.
Administration occurred orally in identically appearing
capsules.
Procedure
When there was no medical objection for participation, par-
ticipants were invited to come for a training day in which the
participants practised the driving tasks and were asked some
questions regarding feelings nausea, dizziness and headache
after driving in the simulator to check for simulator sickness
(i.e. a sort of motion sickness that can be experienced when
driving in a simulator; see for example Stoner et al. (2012) in
Fisher et al. (2011). After the training day, participants visited
the facilities three times (1 day for each condition), with a
washout period of at least 4 days in between. Participants were
asked to refrain from the use alcohol on the day prior to a
testing day and were requested to arrive at experimental ses-
sions well rested (participants were asked if they had had
enough sleep the day before testing).
Drug (morphine, cocaine, marijuana, methamphetamine
and amphetamine) and alcohol screens were performed prior
to experimental sessions upon arrival. Women were also test-
ed for pregnancy. If the outcome of the test allowed the par-
ticipant to proceed with the experiment, he/she was adminis-
tered with 10 mg, 20 mg or placebo dronabinol. On-the-road
driving tests were performed between 2 and 4 h after drug
administration, and simulator driving tests were performed
between 4 and 5 h postdrug administration. Two participants
were tested per testing day. Participants first drove on the road
for 1 h and then in the simulator.
Simulator driving
Test rides were conducted in a (fixed-base) ST Software driv-
ing simulator consisting of a mock-up car with original con-
trols (three pedals, clutch, steering wheel, safety belt, indicator
and hand brake) linked to a dedicated graphics computer,
registering driver behaviour, while the road environment and
dynamic traffic are computed at 30 Hz+. Participants had a
210° view of the road environment. Other vehicles in the
simulated world interacted with each other and the simulator
car autonomously and behaved according to hierarchically
structured decision rules that are based on human driving be-
haviour (Van Wolffelaar and Van Winsum 1992).
On a rural road of approximately 30 km with a posted
speed of 100 km/h, the road tracking task was conducted.
The road consisted of a two-lane straight road with a normal
traffic density. The main parameter was weaving as measured
by SDLP.
In the virtual car following the test adapted fromBrookhuis
et al. (1994; see Veldstra et al. 2009), the participants were
instructed to follow a lead car (posted speed 80 km/h) at a
short but safe distance. The lead car was programmed to ac-
celerate and decelerate within a randomly varied frequency
between 0.025 and 0.05 Hz (i.e. a cycle of 20–40 s). Partici-
pant responses to the speed changes (between 60 and 80 km/h)
of the lead car were measured by assessing the coherence (the
extent to which the pattern of speed changes of the lead and
follow car correspond), the gain (degree of over- or
underreaction to speed changes of the lead car; when there is
an overreaction the gain is larger than 1, while at an
underreaction the gain is smaller than 1) and, most important-
ly, the time to speed adaptation (the reaction time of the fol-
lowing car as response to speed changes of the lead car).
On-the-road driving
Participants operated a specially instrumented vehicle. The
vehicle was equipped with an electro-optical device mounted
at the rear back of the car to continuously measure lateral
distance of the vehicle to the left lane line so as to measure
SDLP in the road tracking task. The signal of the device was
digitised at a rate of 4 Hz to an on-board computer disk and
offline edited by removing all data segments that revealed
signal loss, disturbance or occurrence of passing manoeuvres
directly (see for example Bosker et al. 2012a).
An optical distance sensor (DME 2000) was placed in the
grill of the instrumented car for measurements in the car fol-
lowing task. The sensor emitted laser signals in the direction
of a reflection board mounted on the leading vehicles towing
bracket. Distance was deduced from the time lapse between
the transmission and receipt of the signal at the receiving end
of the distance sensor. Velocity of the leading vehicle was
transmitted via telemetry to the following vehicle and stored
on a computer disk along with the velocity of the following
vehicle and headway. Speed signals collected during manoeu-
vres entered a power spectral analysis for yielding phase delay
between the vehicle’s velocities at the manoeuvre cycle
frequency.
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Both the road tracking task and the car following task were
performed in the right-hand lane of a relatively straight two-
lane motorway with a normal traffic density. In the road track-
ing task, participants drove approximately 1 h under the in-
struction to keep a constant speed of 95 km/h and to drive in
the centre of the lane as well as possible. In the car following
task, participants drove for approximately 25 min behind a
lead vehicle while maintaining a constant distance. The lead
vehicle was under an investigator’s control, who initiated each
manoeuvre by activating a microprocessor-driven cruise con-
trol which was set to maintain a constant speed of approxi-
mately 100 km/h. Sinusoidal speed changes reached an am-
plitude of −10 % and fell within a frequency of 0.2 Hz (50 s).
Responses to speed changes were assessed by deducting the
coherence, gain and delay.
Pharmacokinetic assessments
Blood samples (8 mL) were collected 1.5, 4.25 and 6 h after
drug intake. The blood samples were centrifuged and serum
was frozen at −20 °C until analysis. THC, 11-hydroxy THC
(11-OH-THC) and nor-9-carboxy-THC (THCCOOH) con-
centrations were determined afterwards using solid-phase ex-
traction and gas chromatography with mass spectrometric
(GC-MS) detection with limits of detection/limits of quantifi-
cation of 0.24/0.73, 0.11/0.26 and 0.98/2.99 ng/mL, respec-
tively (Mauden et al. 2000). The sum of molar concentrations
of THC and 11-OH-THC was used to evaluate any confound-
ing effects of cannabinoid concentrations between on-the-road
(OR) and simulated (SIM) driving.
Data analysis
All statistical analyses were conducted by means of SPSS 16
for Windows. Averages were subjected to a general linear
model (GLM) repeated measures analysis with test environ-
ment (two levels) and treatment (three levels) as within-
subject factors. If Mauchly’s test indicated that the assumption
of sphericity was violated, the degrees of freedom were
corrected using the Greenhouse-Geisser correction.
As Godley et al. (2002) already pointed out, statistically
non-significant results validate the driving simulator. Howev-
er, a non-significant result is not necessarily an indication of a
genuine absence of difference. Lack of power due to insuffi-
cient sample size, and therefore insufficient statistical power,
could also account for the results. Due to this limitation, we
need information relating not only to the question of whether
or not an effect exists but also to the magnitude of this effect.
This is typically accomplished by estimating the effect size
(Rosnow and Rosenthal 2009). In this paper the η2p was used
to calculate the effect size for F tests and interpreted using the
guidelines provided by Cohen (1988). When the difference
between on-the-road driving and simulator driving was non-
significant and the effect size could be considered too small to
be meaningful (e.g. η2p≤0.01), correspondence in absolute
terms could be claimed. Relative validity was established by
comparing treatment effects for both driving conditions. If
treatment effects were comparable, validity in relative terms
could be claimed.
When evaluating the effect of a psychoactive substance on
driving performance, SDLP is an important outcome measure.
When evaluating the effects of drugs on performance, it is
common to look at the treatment effect (e.g. the treatment
SDLP effect minus placebo SDLP) and test for equivalence
of the effect to alcohol-induced effects with a so-called equiv-
alence test (Mascha and Sessler 2011). In this test, the equiv-
alence of drug effects -i.e. the difference to the placebo- is
compared to a criterion level that is established in an alcohol
reference study. For the on-the-road study, the alcohol criteri-
on level is based on outcomes generated in a study conducted
by Louwerens et al. (1987) in which the influence of 0.5
permille alcohol on SDLP was tested on the road. For the
equivalence test in simulator driving alcohol criterion out-
comes reported on alcohol and simulator driving as reported
by Veldstra et al. (2011) were used. Equivalence is tested by
assessing if the preestablished criterion levels fall within the
95 % confidence interval of the drug effects. If this is the case,
then the drug effect is considered to be clinically relevant
(Mascha and Sessler 2011). Since this test is an important part
of the assessment of the relevance of the effects found either
by a driving simulator or while driving on the road, outcomes
of equivalence tests were also compared in the current study.
Results
Pharmacokinetics
Average THC, 11-OH-THC and THCCOOH concentrations
are displayed in Table 1. There was a significant treatment
effect of THC (F1.19=14.30, p=0.001). Also, there was a sig-
nificant effect of time after dosing on THC in serum (F (2,
19)=6.59, p=0. 016); THC in serum was at a maximum at
1.5 h after drug intake and decreased after that. There was no
significant difference in sum of molar concentrations of THC
and 11-OH-THC between the on-the-road driving test (OR=
2–4 post drug) and simulator driving test (SIM=4–5 post
drug; F (2,19)=1.05, p=0.38).
Road tracking
Absolute validity
As can be seen in Table 2, SDLP in the simulator was higher
than on the road. However, this difference was non-significant
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and coincided with a very low effect size giving support for
absolute validity.
Relative validity
SDLP treatment effects (that is dronabinol minus placebo ef-
fect) differed non-significantly between driving conditions for
both dosages (F (1.20)=0.37, p=0.55, η2p=0.02 and F
(1.20)=.05, p=0.83, η2p=0.002 for 10 and 20 mg, respective-
ly). Effect sizes were very small for the 20-mg dronabinol
treatment effect, but a bit higher for the 10-mg dronabinol
treatment effect. There was no interaction effect for treat-
ment×driving condition (see Table 2) indicating that treatment
effects were not depended on driving condition. However,
when analysing treatment effects for simulator and on-the-
road driving separately, an important difference stood out.
Although both driving conditions showed a significant main
effect of dronabinol on SDLP (F (2.42)=7.17, p=0.002, η2p=
0.26 and F (2.42)=3.31, p=0.05, η2p=0.14 for on-the-road
driving and simulator driving, respectively), the strength of
the treatment effect differed. In the on-the-road driving condi-
tion, both dosages differed significantly from placebo (F
(1.21)=6.31, p=0.02, η2p=0.23 and F (1.21)=14.69, p=
0.001, η2p=0.41 for 10 and 20 mg dronabinol, respectively),
whereas in the simulator driving condition, only the highest
treatment dosage of 20 mg dronabinol (F (1.21)=4.94, p=
0.04, η2p=0.19) differed significantly from placebo and the
lower dosage did not (10 mg: F (1.21)=0.86, p=0.36, η2p=
0.04). This is also illustrated in Fig. 1.
The figure also illustrates that the 95 % confidence
intervals that are used for equivalence testing seem to
differ between the two testing conditions. The confidence
intervals are wider and upper bounds are higher in the




Comparing coherence in absolute terms showed no significant
differences between driving conditions. Since the effect size
was also smaller than the preset level of 0.01, absolute validity
could be established.
Table 1 Average (SE) THC, 11-OH-THC and THCCOOH concentrations in serum (μg/L) after dronabinol treatment 1.5, 4.25 and 6.0 h postdrug
intake
Dronabinol treatment Time postdrug (h)
1.5 4.25 6.0
THC 11-OH-THC THCCOOH THC 11-OH-THC THCCOOH THC 11-OH-THC THCCOOH
10 mg 5.65 (1.79) 4.77 (0.62) 36.83 (6.45) 2.84 (1.79) 2.33 (0.62) 30.39 (6.47) 2.48 (1.79) 1.98 (0.62) 26.52 (6.47)
20 mg 7.52 (1.75) 6.25 (0.62) 43.71 (6.33) 3.74 (1.79) 3.50 (0.62) 37.39 (6.47) 4.20 (1.87) 3.49 (0.65) 41.38 (6.77)










OR 19.58 (0.81) 20.99 (0.85) 22.05 (0.91) F (1.19)=0.15, p=0.71,
η2p=0.008
F (1.55)=0.23, p=0.74,
η2p=0.01SIM 20.27 (0.87) 21.13 (1.07) 23. 27 (1.41)
Car following
Coherence OR 0.93 (0.006) 0.91 (0.009) 0.92 (0.007) F (1.10)=1.94, p=0.19,
η2p=0.19
F (2.20)=1.21, p=0.32,
η2p=0.11SIM 0.90 (0.02) 0.91 (0.01) 0.87 (0.02)
Gain OR 1.22 (0.03) 1.19 (0.03) 1.30 (0.05) F (1.11)=20.35, p=0.01,
η2p=0.64
F (2.22)=1.78, p=0.19,
η2p=0.14SIM 1.01 (0.02) 1.02 (0.03) 0.99 (0.02)
Delaya OR 2.75 (0.17) 3.70 (0.26) 3,20 (0.35) F (1.10)=6.14, p=0.03,
η2p=0.38
F (2.19)=0.96, p=0.40,
η2p=0.09SIM 2.29 (0.15) 2.41 (0.20) 2.73 (0.25)
a Reaction time to speed changes of the lead car (s)
Psychopharmacology (2015) 232:2911–2919 2915
Coherence: relative validity
There was no interaction effect for treatment×driving condi-
tion (see Table 2) indicating that treatment effects were not
depended on driving condition. When analysing the treatment
effects for both on-the-road driving and simulator driving sep-
arately, no treatment effect for both tasks (F (2.26)=1.11, p=
0.34, η2p=0.08 and F (2.40)=2.26, p=0.12, η
2
p=0.10 for on-
the-road and simulator coherence, respectively) were found,
indicating relative correspondence.
Gain: absolute validity
The average gain as reaction to the lead car speed changes was
significantly higher on the road than in the simulator (see
Table 2) indicating that there was no correspondence between
the driving conditions in absolute terms.
Gain: relative validity
There was no interaction effect for treatment×driving condi-
tion (see Table 2), and separate testing for on-the-road and
simulator car following revealed that there was no treatment
effect for both driving conditions (F (2.26)=2.23, p=0.12,
η2p=0.15 and F (2.42)=0.98, p=0.38, η
2
p=0.05 for on-the-
road and simulator gain, respectively).
Delay: absolute validity
The average reaction time to the speed changes of the lead car
was higher on the road than in the simulator (see Table 2)
indicating that there was no correspondence between the driv-
ing conditions in absolute terms.
Delay: relative validity
Although there was no significant interaction effect, separate
analyses of both driving conditions show differential effects of
treatment on reaction time. There was a main treatment effect
for dronabinol on reaction time when driving in the simulator
(F (2.40)=3.31, p=0.05, η2p=0.14) but not for driving on the
road (F (2.26)=2.53, p=30.10, η2p=0.16). When looking at
Fig. 2, it becomes clear that reaction time to speed changes
increased dose dependently when driving in the simulator,
only reaching significance at the highest dosage (20 mg).
However, on-the-road reaction time increased significantly
in the 10-mg dronabinol condition but not for the 20-mg
condition.
Discussion
In the current study, we investigated whether or not the driving
simulator was a sensitive instrument for assessing drug-
induced effects on car driving by comparing effects of a drug
on similar measures taken in the simulator and on the road.
The tasks used to compare driving environments were the
‘road tracking task’ as devised by O’Hanlon et al. (1982)
and the ‘car following task’ adapted from Brookhuis et al.
(1994).
We used the two-threated approach to validity testing pro-
posed by Blaauw (1982). This means that averages in the
simulator and on the road were compared. If averages did
not differ significantly, then the simulator was considered to
Fig. 1 Average SDLP difference to placebo (95 % CI) as a function of
dronabinol treatment when driving in the simulator versus on the road and
alcohol reference lines: A 0.5‰ alcohol as measured on the road by
Louwerens et al. (1987) and B 0.5‰ alcohol as measured in the simulator
by Veldstra et al. (2011)
Fig. 2 Average reaction time to speed changes (difference to placebo)
and 95 % CI as a function of dronabinol treatment. Driving in the
simulator versus on the road
2916 Psychopharmacology (2015) 232:2911–2919
be valid on an ‘absolute’ level of correspondence. If averages
were influenced by an independent variable in the same way,
then the simulator was considered to be valid on a ‘relative’
level of correspondence. In the case of the current research,
the simulator was considered as valid on a relative level when
the drug-induced effects that were found on the road were also
seen in the simulator.
The results of the road tracking task showed that SDLPwas
comparable between driving conditions on an absolute level
since averages did not significantly differ and the effect size of
the main effect equalled the preset level of 0.01 (effect size
considered too small to be meaningful). Also, the average
treatment effects were not significantly different. Even so,
there was a difference between on-the-road and simulator
driving regarding the strength of the treatment effects. On
the road, both treatment conditions significantly decreased
performance on SDLP, but in the simulator, only the 20-mg
dronabinol treatment effect had a statistically significant
effect.
This lack of effect in the simulator for the lowest
dronabinol dosage can be explained by a higher variance in
the simulator than on the road as was illustrated by the differ-
ence in size of the 95 % confidence intervals around the treat-
ment averages. It is relevant to find out if the higher variances
in the simulator are due to random error or due to variance that
can be attributed specifically to simulator driving since the
upper bound of the confidence interval is used to test for
equivalence of drug-induced impairments to alcohol-induced
impairments so as to be able to assess clinical relevance of the
results. In this case, for example, the higher upper bound of
the 95 % confidence interval for the 20-mg treatment condi-
tion in the simulator would lead to more extreme conclusions
about the possible impairing effects of the treatment on driv-
ing performance than equivalence tests for on-the-road driving
data would.
Another possible explanation for not finding an effect at a
lower dose of dronabinol on SDLP in the simulator compared
to results found on the road is that not the driving environ-
ments but the drug concentrations differed. Even though pre-
vious research had shown that orally administered THC con-
centrations in blood peak after 1.5 h postdrug intake and then
remain stable for about 4–5 h (Haney et al. 1999), average
THC levels in serum were already decreased at 4.25 h post-
drug intake. However, absolute differences in mean THC con-
centrations during on-the-road driving and simulated driving
where minimal, i.e. 1 ng/mL after the 10-mg dose and about
4 ng/mL after the 20-mg dose. Therefore, differences in THC
concentration may have caused some additional variance but
are not likely to fully account for differential effects of
dronabinol 10 mg during actual and simulated driving tests.
Car following results were less clear in terms of compara-
bility. Coherence was comparable between driving conditions
but phase and delay were not. Coherence was high and
comparable in relative terms since both simulator and on-
the-road driving condition showed no treatment effects. But
also in absolute terms, coherence results were comparable
since average treatment effects were non-significantly differ-
ent—at least for the highest dose (20 mg dronabinol); the
treatment effect of 10 mg dronabinol showed an effect size
above the preset level of 0.01. Gain was not comparable in
absolute terms since it was higher on the road than in the
simulator, but was in relative terms since for both on-the-
road driving and simulator driving, no treatment effect was
found. For reaction to speed changes of the lead car, however,
neither absolute nor relative correspondence was found. An
increase in reaction time with dose was found when driving in
the simulator, but not on the road.
These results indicate that participants were well able to
follow the lead car in both the road and simulator driving
conditions irrespective of dronabinol treatment. However,
they tended to overreact to speed changes of the lead car more
on the road as compared to in the simulator and had longer
reaction times to speed changes of the lead car. These differ-
ences in car following performance in absolute terms are not
problematic since the treatment effects of the car following
task are generally not compared on an absolute level but in
relative terms. However, since the reaction time to speed
changes of the lead car was not comparable in relative terms
either, one could conclude that car following results from sim-
ulator and on the road driving did not correspond.
It could be that differences in the way the car following task
was presented on the road versus in the simulator influenced
the outcome measures. For example, in the on-the-road car
following task, participants were subjected to six to ten cycles
of sinusoidal speed changes of the lead car in 25 min, whereas
in the simulator car, the same amount of cycles were intro-
duced in about 10 min of driving. The cycles in the simulator
were also a bit shorter (i.e. 20–40 s) compared to on-the-road
driving (50 s). Also, the posted speed in the simulator was
lower (80 km/h) than on the road (100 km/h). Moreover, the
simulator car following task is more controlled than the on-
the-road driving task. Measurement disturbances such as other
cars driving too slow in front of the lead car or cars merging
between the lead and follow cars are not present in the
simulator.
Also, the ability to estimate distance was different in the
simulator versus on the road since the stereoscopic input dif-
fers between the two driving conditions. The simulator has a
2D vision on the car in front whereas in real life this is 3D.
This might make it more difficult to perform this task in the
simulator than on the road.
Another possible explanation is again that not the task but
drug effects differed. However, this does not explain why a
dose-related treatment effect of dronabinol on reaction time to
speed changes of the lead car was found in the simulator and
not or to a lesser extent on the road. The latter finding would
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actually argue for a better sensitivity of the simulator car fol-
lowing task in picking up drug-induced effects as compared to
the on-road driving car following task.
Limitations
For practical reasons, the on-the-road driving task always pre-
ceded the s imula tor d r iv ing task . Th is lack of
counterbalancing may have influenced the outcomes. Further-
more, as explained, small differences in drug-induced effects
may have occurred due to taking the simulator test somewhat
later than the on-the-road driving test, which in turn may have
affected the outcomes. Also, the investigated group was quite
hetrogeneous since both occasional and regular cannabis users
were included. This hetrogeneity of groups could have influ-
enced the influence of the drug on performance somehow
despite the within-subjects design.
Furthermore, factors that influence driving in both devices
differentially could have influenced outcomes. Although the
aim of the study was to investigate if outcomes of the two
driving tasks (OR and SIM) could generate similar results
irrespective of these factors, they are worth mentioning as
potential limitations.
First, the devices can influence behaviour on amotivational
level differentially. In the on-the-road driving task, for exam-
ple, an instructor is sitting next to the participant, whereas in
the simulator, there is no instructor present. This may prompt
some participants to try and perform better for the instructor in
the on-the-road driving task. On the other hand, the fact that
one cannot have an accident in the simulator could influence
motivation in the simulator differentially than while driving
on the road. Although the chances of becoming involved in an
accident are also nihil on the road since an instructor is there to
intervene-, the percieved risk may be different i.e. driving in a
real car may prime reactions that are associated with real driv-
ing while the simulator may not.
Second, the aforementioned difference in sensorial input
between the simulator and on-the-road driving could also in-
fluence performance differentially since on-the-road driving
occurs in a 3D and simulator driving in a 2D setting. Also,
there is no tactical input in the simulator (which was fixed-
based) while on the road there is. Also, for simulator driving
participants can differ in their the susceptibility to simulator
sickness, experience with driving in a simulator or
gaming experience which can create extra variance that is
not present in the on the road driving task. Another difference
between the two devices is the controllability of traffic circum-
stances. In the simulator, everything can be controlled for, the
weather, lighting, traffic flow etc., that cannot be controlled
for on the road, leaving a gap between driving conditions on
the road versus in the driving simulator.
For future research, it may be interesting to find out if the
difference in variance between simulator and on-the-road
driving that seemed to be present in this data is due to random
error or due to some of the above-described factors in simula-
tor driving.
Conclusion
The driving simulator was proven to be sensitive for demon-
strating dronabinol-induced effects particularly at higher
doses. Treatment effects of dronabinol on SDLP were compa-
rable with driving on the road but inter-individual variability
seemed higher in the simulator than on the road which may
have potential effects on the clinical inferences made from
simulator driving. Car following on the road and in the simu-
lator were, however, not comparable.
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